Reported about 7 hours ago
WeightWatchers' stock surged over 170% following its plans to produce cheaper compounded versions of popular weight-loss drugs like Ozempic and Wegovy. Despite this, analysts warn that this approach may not represent a sustainable long-term business model, as the compounded drugs could be impacted by restrictions once the original formulations are no longer on the FDA's shortage list. The company's core business could suffer as these drugs potentially cannibalize its traditional dieting programs.
Source: YAHOO